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1. Introduction
Atherosclerosis is an endothelial dysfunction induced by elevated and modified low-density
lipoproteins (LDL), free radicals, infectious microorganisms, shear stress, hypertension, tox‐
ins after smoking or combinations of these and other factors[1], which is characterized by
decreased nitric oxide synthesis, local oxidation of circulating lipoproteins and their entry
into the vessel wall[2]. Intracellularreactive oxygen species similarly induced by the multi‐
ple atherosclerosis risk factors lead to enhanced oxidative stress in vascular cells and further
activate intracellular signaling molecules involved in gene expression[3].
Up regulation of celladhesion molecules facilitates adherence of leukocytes to the dysfunc‐
tional endothelium and their subsequent transmigration into the vessel wall.The evolving
inflammatory reaction is instrumental in the initiation of atherosclerotic plaques and their
destabilization. There are evidence[4] supporting a pathophysiological role of T cells, B cells
and macrophages in the development of atherosclerosis in general[5].
2. Atherogenesis and cardiovascular diseases
Decades ago, the endothelium was considered just a barrier non thrombogenic, vascular
control which was attributed primarily to the sympathetic nervous system and circulating
vasoactive hormones. The discovery that the endothelium synthesizes important vasodila‐
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tors such as nitric oxide and prostacyclin, and vasoconstrictors such as endothelin, aroused
great interestin endothelial function and role of vascular control, both in physiological proc‐
esses and in pathological conditions. The model ‘response to injury’ of the endothelium ex‐
plains more precisely this complex pathophysiological mechanism. In this model the
endothelium is injured by hemodynamic stimulus, such as hypertension, or bychemical at‐
tack, such as in smoking, begins to operate in a manner dysfunctional. This endothelial dys‐
function leads to compensatory responses that alter the normal homeostatic properties of
the endothelium to a reduction in nitric oxide synthesis and an increase inpermeability of
the endothelium which binds to LDL cholesterol in the vessel wall[6]. Adhesion molecules
begin to be expressed on the surface of the endothelium will lead to attraction of monocytes
and lymphocytes to the arterial wall[7].
LDL  modified  by  oxidation  is  a  major  cause  of  injury  to  the  endothelium.  Many  au‐
thors believe that  LDL oxidation does not  take place in the circulation,  and therefore it
must  occur  in  the  subendothelial  space  of  the  arterial  wall.  After  being  trapped in  the
artery  wall,  it  is  internalized  by  macrophages  via  the  scavenger  receptor  surfaces  of
these  cells  which leads  to  the  formation of  foam cells.  Inflammation mediators  such as
tumor necrosis  factor  α,  interleukin-1  and macrophage colony-stimulating factor  further
increase  the  binding  of  LDL  to  the  endothelium  and  smooth  muscle  and  increase  the
transcription  of  the  LDL  receptor  gene.  Experimental  studies  in  mice  show  that  oxi‐
dized  LDL  (oxLDL)  promotes  atherosclerosis,  however,  clinical  trials  of  antioxidants
were not effective in reducing cardiovascular events[8],[9].Increased levels of  oxLDL are
presentin  human  gingival  crevicular  fluid  compared  to  plasma  of  healthy  individuals,
indicating  that  oxLDL  could  be  generated  in  inflamed  extra-arterial  tissues,  transferred
to the circulation, rapidly taken up into the arterial  wall,  and contribute to the perpetu‐
ation ofatherosclerosis[10].
Early  ‘fatty-streak’  lesions  consist  of  T  cells  and  monocyte-derived  macrophage-like
foam  cells  loaded  with  lipids  and  after  successive  accumulation  of  apoptotic  cells,  de‐
bris  and cholesterol  crystals  forms a necrotic  core.  Initial  lesions most  commonly devel‐
opin  places  where  laminar  blood  flow  is  altered,  as  in  the  bifurcations  of  the  vessels,
which  interferes  with  the  shear  stress  and  adequate  production  of  nitric  oxide[11].  In
these  places,  substances  are  produced  by  the  endothelium  that  promote  adhesion,  mi‐
gration and accumulation of  monocytes  and T cells.  The flow changes,  leading to  a  re‐
duced  shear  stress,  modifies  the  expression  of  genes  such  as  intercellular  adhesion
molecule, platelet derived growth factor B chain[12],[13].
The mature atherosclerotic plaque shows in addition to cells, two distinct structural compo‐
nents: a lipid core, very dense, and fibrous cap that is its fibrotic component. The higher the
fibrotic component less prone to disruption (less unstable) is the atherosclerotic plaque. The
lipid core is highly thrombogenic. When it makes contact with the blood stream by rupture
of the fibrous cap or endothelial erosion, occurring phenomena of platelet adhesion and ag‐
gregation, thrombin generation and fibrin, with underlying thrombus formation, which rep‐
resents the common starting point of acute coronary syndromes[14].
Current Trends in Atherogenesis82
Apart from traditional risk factors, numerous evidences have shown an association between
atherosclerosis and genetic variants which should allow in the future, a new understanding
of the molecular mechanisms of cardiovascular disease[15].
3. Schistosomiasis mansoni infection may affect the natural history of
atherogenesis
Infections of Schistosoma mansoni, the adult worms significantly reduced atherogenesis in
apolipoprotein E gene knockout (apoE(-/-)) mice. These effects occurred in tandem with a
lowering of serum total cholesterol levels in both apoE(-/-) and random-bred laboratory
mice and a beneficial increase in the proportion of HDL to LDL cholesterol. The serum cho‐
lesterol-lowering effect is mediated by factors released from S. mansoni eggs, while the pres‐
ence of adult worms seemed to have little or no effect. High levels of lipids, particularly
triacylglycerols and cholesterol esters, present in the uninfected livers of both random-bred
and apoE(-/-)mice fed a high-fat diet were not present in livers of the schistosome-infected
mice[16].ApoE-deficient mice chronically exposed to the eggs of Schistosomamansoni over a
period of 16 weeks showed thattotal serum cholesterol and low-density lipoprotein (LDL)
were reduced in egg-exposed ApoE-deficient mice fed a diet high in cholesterol compared
to unexposed controls. However, exposure to eggs has no effect on atherosclerotic lesion
size or progression in these animals. Macrophages isolated from egg-exposed mice had an
enhanced ability to take up LDL but not acetylated LDL (acLDL). This suggests that schisto‐
some eggs alone may alter serum lipid profiles through enhancing LDL uptake by macro‐
phages, but these changes do not ultimately affect atherosclerotic lesion development[17].
Previous studies have shown that people infected with schistosomiasis have lower levels of
serum cholesterol than uninfected controls. In human beings the first manifestations of car‐
diovascular disease from atherogenesis arise at an advanced stage of atherosclerosis. How‐
ever, patients with hepatosplenic schistosomiasis mansoni have abnormal lipid
peroxidation, with elevated erythrocyte-conjugated dienes implying dysfunctional cell
membranes, and also imply that this may be attenuated by the redox capacity of antioxidant
agents, which prevent accumulation of plasma malondialdehyde (MDA)[18]. These lipid
metabolism changes affect the natural history of atherogenesis including the risk factors.
The alterations in the arterial wall occur during the subclinical period of atherogenesis, char‐
acterized by progressive thickening of the endothelium. This endocrine organ is responsible
for physiological processes that are vital to vascular homeostasis[19].
When risk factors exist, endothelial thickening can be detected already in childhood, and
can be predictive of cardiovascular events in adults[20]-[22]. Since the first anatomopatho‐
logical description, several articles have been published associating ultrasound measure‐
ments (intima-media thickening – the identifiable portion of the endothelium) with
cardiovascular diseases[23].
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The accuracy, reproducibility and rapidity of Doppler ultrasound have made this method a
powerful tool for early diagnosis, as well as in the monitoring of atheroscletrotic lesions and
even when evaluating results in population studies[24].
There are already several well-established risk factors for atherosclerosis, such as hyperten‐
sion, dyslipidemia, smoking and diabetes[25]. However, there are other factors which are
still controversial as to the predictive value of findings. Among those factors, bacterial (C.
pneumoniae, H. pylori), as well as viral (herpes simplex, Epstein-Barr) and parasitic (T.cruzi,
S.mansoni) infections[26].
Schistosomiasis, an endemic disease in several regions in the world and with high preva‐
lence in Pernambuco, Brazil, has been the target of research studies on disease prevention,
clinical and surgical treatments to alleviate the effects of hypertension on the portal system,
hypersplenism and child hypoevolutism[27],[28].
Important alterations have been demonstrated in the lipid profile of those who present with
advanced disease[29]. Speculations are made as to whether those findings could influence
the behavior of the intima-media complex. On the other hand, whether the lipid alterations
in human hepatosplenic schistosomiasis mansoni (HSM) patients interfere with atherogene‐
sis has been investigated[30].
The hepatic lesions in patients with hepatsplenic schistosomiasis mansoni produce changes
in the lipid profile. There is a tendency toward normalization after surgical treatment of por‐
tal hypertension[31]. Since those changes are related to the extent of the lesion to endothelial
cells, Doppler ultrasound is used to assess whether those HSM influence intima-media
thickness in humans[32].
The relation of lipoproteins to atherosclerosis is known[30]. However, several years passed
before an insight was achieved into the association between the biochemical findings and
the structural lesions found in the wall, especially in the vascular endothelium. The partici‐
pation of cells such as lymphocytes, macrophages and monocytes is decisive in the inflam‐
matory component of that disease.
Hypertension, dyslipidemia, diabetes and smoking constitute risk factors already largely as‐
sociated with atherogenesis. The interfaces of atherosclerosis with infections are very com‐
plex. This is due to the mechanisms used by the infectious agents and the different forms of
response from the host organism. Infection and inflammation induce an acute phase re‐
sponse, which, in turn, leads to alterations in lipids and proteins. These changes initially
protect the host from the deleterious effects of bacteria, viruses and parasites; however, if
extended, they could contribute to atherogenesis[33].
Changes take place in the metabolism of total and HDL cholesterol and in their reverse
transport over the course of an infection. The responses are not fully understood, but lipopo‐
lysaccharides (LPS) and cytokines are known to reduce total cholesterol serum levels and
produce various effects in rodents[34].
The incidence of coronary artery disease and stroke is higher in patients with chronic infec‐
tions. Some lesions are supposedly produced by the infectious agent itself, as in the case of
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C. pneumoniae and Cytomegalovirus, while other lesions seem to be induced by humoral
mechanisms, as in the case of H. pylori and chronic urinary, respiratory and oral infec‐
tions[35].
Since atherosclerosis itself is an inflammatory disease, and given that infections induce a
proatherogenic change in lipoproteins, a cycle is started that tends to aggravate the athero‐
sclerotic lesions[36].In certain instances of bacterial infections, beneficial effects can be found
from the alterations in lipoprotein metabolism. The conjugation of LPS to lipoproteins pro‐
tects animals from hypotension, LPS-induced fever and death.
Regarding parasite infestations, complex mechanisms are triggered, since both the direct
action of the parasite and immune reactions induced by its  presence have been demon‐
strated[37].
Atherosclerosis-resistant rats developed early atherosclerotic plaques when infested with
T.cruzi, while rats that were susceptible to atherosclerosis sustained fewer atherosclerotic le‐
sions when infested with S. mansoni. On the basis of those findings, it is postulated that in‐
fection by S. mansoni may produce a protective effect against atherosclerosis[38].
The IMT has been study in infectious processes[39].  The attempt to identify early mark‐
ers of atherosclerosis has been the object of several studies.  The ankle-arm index, which
has been used since the 1970's  to  assess  blood flow to the lower limbs,  has been intro‐
duced in  the  armamentarium of  cardiologists  and atherogenesis  experts  as  a  marker  of
diffuse atherosclerosis[40].
Brachial artery distensibility, coronary flow reserve, pulse wave analysis, pulse wave veloci‐
ty and plethysmography have also been used to detect endothelial dysfunction and also
considered to be risk markers for cardiovascular disease[16].
Some authors have proposed the validation criteria of surrogate markers for clinical anal‐
ysis. They established three conditions for validity: the first is that the marker should be
more sensitive and more readily available than clinical conclusions, in addition to being
easy  to  assess,  preferably  through noninvasive  methods.  Second,  the  causative  relation‐
ship between the marker and the clinical conclusions should be established on epidemio‐
logic  and  pathophysiological  bases,  as  well  as  clinical  studies.  It  is  a  prerequisite  that
patients  with  and  without  vascular  disease  exhibit  differences  in  the  marker  readings.
Third,  in  intervention  studies,  expected  clinical  benefits  (benefit  assessment)  should  be
anticipated  from changes  observed  in  the  markers.  This  last  argument  implies  that  the
development  of  markers  is  not  only  a  matter  of  time/cost.  Moreover,  other  diagnostic
methods  for  measuring  IMT such  as  the  transesophageal  echocardiogram,  intravascular
ultrasound  and  magnetic  resonance  imaging,  in  addition  to  being  more  expensive  and
more invasive, are not appropriate for screening[21],[41].
The Doppler ultrasound scan with an automatic calibrator becomes minimally sonographer-
dependent. Normal limits for IMT measurements have been established as between 0.4 mm
and 1.0 mm, whereas those above 1.5 mm are interpreted as a plaque. The results are imme‐
diately ready for printout or to be saved on an HD or CD-ROM for occasional and future
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comparisons. Questions that might be raised concerning loss of sensitivity with this type of
equipment have already been addressed in a comparison with conventional machines[42].
The carotid artery ensures easy access to the examiner; for its anatomy, as it is a superfi‐
cial  artery and follows a more or less straight path along the cervical  segment,  in addi‐
tion  to  being  a  vessel  with  abundant  elastic  fibers  that  respond  promptly  to
hemodynamic "stress"[23].
A study with populations at difference ages showed that IMT increases at a rate of [IMTmm
= 0.009 x age+0.35], i.e., it is a biological phenomenon that can be quantified[30].
The means for IMT values of common and internal carotids are higher among patients with
some risk factor (hypertension, age and smoking). This pattern occurs in normal subjects
and patients with hepatosplenic schistosomiasis mansoni clinical and surgical treated, but
this phenomenon is not observed in these patients without any treatment[43]. These find‐
ings lend support to the hypothesis that hepatosplenic schistosomiasis mansoni may be a
protective factor against atherogenesis[30].
4. HIV infection may affect the natural history of atherogenesis
Individuals infected with human immunodeficiency virus (HIV) have a different condition
of life of the population free of infection with regard to morbidity and mortality from pre‐
mature atherosclerosis and cardiovascular, and its related complications[44]-[47].
Atherosclerosis is a systemic disorder characterized by the formation of cholesterol plaques,
especially at the level of the intima of the arterial wall. All arteries can be affected, but the
clinical consequences are more important at the level of coronary and carotid arteries of the
lower limbs (LL).
Arterial  disease  is  chronic,  along with coronary artery disease and ischemic stroke,  one
of three clinical manifestations of the same pathophysiological process: atherothrombosis.
The  classic  risk  factors  of  atherosclerosis  are:  smoking,  hypertension  (HTN),  diabetes
mellitus  (DM),  hypercholesterolemia,  and  obesidade[48].  Atherosclerosisisamajor  cause
ofmortality worldwidemobility,  andlow life expectancyis mainly due to heart attack and
stroke(CVA)[49]-[51].
The morbidity and mortality among HIV-infected individuals with advanced disease was
very high until the advent of potent antiretroviral therapy (HAART), which produced an
improvement in quality and increased expectation [52]-[55].
This  therapy,  however  has  been  associated  with  a  variety  of  adverse  effects,  which  in‐
clude metabolic changes such as changes lypodistrophy, insulin resistance, lactic acidosis
and dislipidemia[46],[56]. All these changes are pro-atherogenic and its consequences are
often fatal.  The development of cardiovascular disease in HIV-infected individuals is re‐
lated  to  endothelial  dysfunction.  This  dysfunction  and  accelerated  atherosclerosis  is  a
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consequence  of  HIV  itself  that  activates  the  endothelial  directly  or  indirectly  through
production of citocinas[57].
There is evidence that both pathophysiological HIV to antiretroviral therapy may affect the
profile lipídico[58],[59], insulina resistance[60],[61] and the response of vasodilatação[62].
The increased mortality in individuals with HIV due to cardiovascular events in young pa‐
tients, often without classic risk factors for atherosclerosis, is cause for concern and the sub‐
ject of new studies[44],[46].
Antiretroviral therapy is associated with pro-atherogenic metabolic abnormalities such as
metabolic syndrome, type II diabetes, abnormal distribution of body fat, these conditions al‐
so associated with arterial disease coronariana[63],[64]. Some studies suggest that class of
drugs known as protease inhibitors (PI) can be associated with premature atherosclerosis
and cardiovascular events, vasculares[47]. It is not clear, but what is the real contribution of
ART in HIV and increased risk of cardiovascular disease.
The measurement of intima-media complex (IMT) by ultrasonography (USG) is a nonin‐
vasive marker of early atherosclerosis and may reflect the increased overall cardiovascu‐
lar risk and is associated with increased risk of acute myocardial infarction (AMI) and /
or AVC[65]-[67].
The IMT can be used as a predictor of atherosclerotic disease in coronary arteries independ‐
ently of classical risk factors: age, sex, smoking, hypertension, dyslipidemia, diabetes and
family history of coronary artery disease (CAD). IMTcan be consideredas a markerfor the
evaluation ofatherosclerosissubclínica[68]-[70].
The study using IMT has been performed in patients with acquired immunodeficiency syn‐
drome (AIDS) in the investigation of risk factors for atherosclerosis as an early marker, but
there are few studies prospectivos[71],[72].
In AIDS patients the automatic measurement of MIC performed in right and left common
carotid, with software determining produces the following measures: average, maximum
and minimum (Figure 1). In this same place three manual measurements can be performed.
Thus, it is possible to calculate the arithmetic mean of the measure in manual right and left
common carotid and the maximum and minimum extent (Figure 2). In the right and left in‐
ternal carotid it can be performed as manual. The gold standard can be represented by the
mean of automatic measurements from the right common carotid (RCA) and left common
carotid (LCA)[73],[74]. We have measured population of 50 years AIDS patients, the MIC
was considered thickened if > 0.8 mm[75] was considered the presence of a thickening dem‐
onstrated plate when WCC > 1.5mm[73],[76].
The ankle-brachial index (ABI) is a simple, noninvasive, high predictive value for peripheral
artery disease and has significant association with risk of cardiovascular mortality. It is a
good method to be safe, reproducible, low cost, outpatient use and validated in the general
population. Early diagnosis of atherosclerosis identifies people at high risk for cardiovascu‐
lar events and thus provides effective treatment and control of factors risco[55].
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Figure 1. Medida automática do CMI em CCD
Figure 2. Medida manual do CMI em CCD
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The reduction of the ABI values below 0.9 is associated with a significantly increased cardio‐
vascular risk, particularly by acute myocardial infarction and ischemic stroke, independent
of other factors[77],[78]. The increase in ABI (> 1.3) is due more to changes in arterial compli‐
ance than the stenosis, which would be responsible for a decrease in ABI. The high preva‐
lence of high ABI in patients with HIV may be mediated by the involvement of vascular
elasticity as well as the formation of atheromatous plaques. A meta-analysis of six retrospec‐
tive studies the ABI has been studied in patients with HIV. The populations were selected
with varying criteria and there was no consensus about the risk factors responsible for ab‐
normal ABI. The increased prevalence of ABI was higher than in the general population. In
the population with HIV/AIDS remains whether the high prevalence of altered ABI is asso‐
ciated with increased incidence of cardiovascular events.
We selected 70 cases with HIV in use antirratrovirais (ARV) for at least five years of service
reference in the State of Pernambuco and 70 controls without HIV, matched by sex and age,
which were assessed by automatic measurement of carotid IMT in and ABI. It was taken in‐
to account the classical risk factors of atherosclerosis, anthropometric measurements and
treatment with protease inhibitors (PI). We performed the analysis of homogeneity of
groups. The groups were homogeneous at the 95% confidence.
The ABI was raised in a single patient in the case group (0.7%) and no change in the control
group ABI. The WCC was not thickened in any individual. There was no statistically signifi‐
cant difference between case and control groups with respect to the ABI and the WCC, even
when considering the type of treatment. There was no significant difference between the
groups regarding presence of atheromatous plaques in the common carotid.
Maggi et al. evaluating patients with HIV and advocate the hypothesis that CMI is thick‐
ened more in the HIV group, which use the IP protocol is the cause of the thickening and
that the lesions found in these patients are similar to arteritis and substantially different
from atherosclerotic plaques[66],[69],[71],[72]. The present study does not confirm this hy‐
pothesis of thickening CMI in patients with HIV. In 70 patients there was no thickening in
the common carotid, while also presenting the same classic risk factors for atherosclerosis,
including having more hypercholesterolemia and hypertriglyceridemia than the control
group. One possible explanation for the lack of thickening of the WCC in this population is
the fact that the patients are young (mean 40.5 years), having long-term treatment (mean
8.16 years), have fewer risk factors than other atherosclerosis studies and found to be clini‐
cally stable (84% had an undetectable current CV with current median CD4 670.57) with less
aggression endothelium.
It can be concluded that HIV-infected individuals do not run a higher risk of atherosclerosis
than the control population, taking into consideration the classical risk factors of atheroscle‐
rosis and the specific characteristics of HIV-infected patients.
The result of this study is essential because as the population was very young, phase detec‐
tion of atherosclerotic disease earlier period can be after cutting realized. The follow-up of a
cohort for a new sectional assessment later is very important for early detection of athero‐
sclerosis in HIV patients on antiretroviral therapy.
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